Clinical Trials
11
Active:7
Completed:3
Trial Phases
2 Phases
Phase 1:8
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (72.7%)Phase 2
3 (27.3%)ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
Phase 2
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: Intravenous Placebo
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 438
- Registration Number
- NCT05070260
- Locations
- 🇺🇸
Black Medical center, Bradenton, Florida, United States
🇺🇸Nova Clinical Research, Bradenton, Florida, United States
🇺🇸Northside hospital, Saint Petersburg, Florida, United States
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
Phase 2
Completed
- Conditions
- SARS-CoV InfectionAcute Respiratory Distress SyndromeCOVID-19ARDS
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT04659109
- Locations
- 🇫🇷
Hôpital de Hautepierre, Strasbourg, France
Acute Ischemic Stroke Interventional Study
Phase 1
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Other: Intravenous PlaceboDrug: Intravenous ACT017 1000 mg
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 160
- Registration Number
- NCT03803007
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Bordeaux,, Bordeau, France
News
Acticor Biotech Repositions Glenzocimab for Myocardial Infarction Treatment
Acticor Biotech is focusing on myocardial infarction with glenzocimab, encouraged by expert feedback on its potential in STEMI treatment.